X @The Wall Street Journal

Financial Performance - Biogen cut its full-year adjusted-earnings expectations [1] - Third-quarter profit rose [1] Product Performance - Strength from Alzheimer's drug contributed to profit increase [1] - Rare-disease treatments contributed to profit increase [1]